PHARMACY

Nix launches first-ever lice tracker

BY Gina Acosta

TARRYTOWN, N.Y. — Just in time for back-to-school season, Prestige Brands is launching the first-ever and only data-driven lice tracker. 

The Nix Lice Tracker is an easy-to-use online tool that combines retail data and crowdsourced outbreak reports from parents and school nurses, as well as Google Trends data to develop a real time map of where lice outbreaks are occurring.

"Unlike the flu and chicken pox, lice outbreaks are not tracked by the CDC because lice are an infestation, not a disease," said Albert Hwang, vice president, marketing at Prestige Brands, Inc. "Nix has developed the first-of-its-kind Nix Lice Tracker, an innovative tool that enables parents and school nurses to track and prepare for lice outbreaks in their community."

The Nix Lice Tracker can be found online at nixlice.com/lice-tracker and is optimized for mobile devices.

Additionally, Nix recently launched pesticide-free Nix Ultra, a safe and effective over-the-counter system that eliminates both traditional and super lice, as well as their eggs.
 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

PHARMACY

Apotex re-enters market with authorized Paxil CR generic

BY David Salazar
WESTON, Fla. — Apotex on Thursday announced that it would be re-entering the market with its authorized generic version of Paxil CR (paroxetine controlled-release) tablets. 
 
Apotex’s authorized generic will be available in 12.5-, 25- and 37.5-mg dosage strengths. The drug had about $126 million in sales for the 12 months ended June 2016, according to IMS Health. 
 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

PHARMACY

Pfizer to acquire AstraZeneca’s small-molecule anti-infectives

BY David Salazar
NEW YORK — Pfizer announced Wednesday that it would be acquiring the development and commercialization rights to AstraZeneca’s late-stage small molecule anti-infectives business, largely outside the United States. 
 
Pfizer will pay $550 million upfront to AstraZeneca upon close of the transaction and a deferred $175 million payment in January 2019. AstraZeneca will be eligible for up to $250 million in milestone payments, as much as $600 million in sales-related payments and tiered royalties on sales of its Zavicefta (ceftazidime-avibactam). 
 
“As we continue to reshape our Essential Health portfolio, we are focusing on areas that further address global public health needs and that complement our core capabilities and experience in therapeutic areas, including anti-infectives,” Pfizer Essential Health group president John Young said.  “The addition of AstraZeneca’s complementary small molecule anti-infectives portfolio will help expand patient access to these important medicines and enhance our global expertise and offerings in this increasingly important area of therapeutics, in addition to providing the opportunity for near-term revenue growth.”
 
The products purchased will be Zavicefta, Zinforo (ceftaroline fosamil), Merrem/Meronem (meropenem), ATM-AVI and CXL. 
 
“This agreement reinforces our strategic focus to invest in our three main therapy areas where we can make the greatest difference to patients’ lives,” AstraZeneca EVP Europe and antibiotics business unit head Luke Miels said. “We’re pleased that our strong science in antibiotics will continue to serve a critical public health need through Pfizer’s dedicated focus on infectious diseases, ensuring these important medicines reach greater numbers of patients around the world.”
 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES